Xenoport, Inc.
3410 Central Expressway
Santa Clara,
CA 95051
United States - Map
Phone: 408-616-7200
Fax: 408-616-7210
Web Site: http://www.xenoport.com
| XenoPort, Inc., a biopharmaceutical company, focuses on developing internally-discovered product candidates that utilize the body’s natural nutrient transporter mechanisms. Its product candidate, XP13512, which is a transported prodrug of gabapentin, is being evaluated in a Phase III clinical program for the treatment of restless legs syndrome, as well as completed a Phase IIa clinical trial for the management of post-herpetic neuralgia; XP19986, which is a transported prodrug of R-baclofen, is being evaluated in Phase II clinical trials for the potential treatment of gastroesophageal reflux disease and spasticity; and XP21279, which is a transported prodrug of levodopa, is in Phase I clinical trial for the treatment of Parkinson’s disease. The company’s preclinical development programs include XP20925, which is a transported prodrug of propofol for the treatment of migraine; and XP21510 for the potential treatment of women diagnosed with menorrhagia or heavy menstrual bleeding. XenoPort has strategic alliances with Astellas Pharma, Inc.; Glaxo Group Limited; and Xanodyne Pharmaceuticals, Inc. The company was founded in 1999 and is based in Santa Clara, California. |
|
| Key Statistics |
| |
| | Pay | Exercised | Dr. Ronald W. Barrett Ph.D., 52
Co-Founder, Chief Exec. Officer |
$
695.00K |
$
1.05M | Mr. William J. Rieflin , 47
Pres |
N/A
| N/A | Mr. William G. Harris , 49
Chief Financial Officer, Principal Accounting Officer and Sr. VP of Fin. |
N/A
| N/A | Dr. Kenneth C. Cundy Ph.D., 48
Sr. VP of Preclinical Devel. |
$
372.00K |
$
207.00K | Dr. David R. Savello Ph.D.,
Sr. VP of Devel. |
$
392.00K |
$
555.00K |
|
|
|
Dollar amounts are as of
31-Dec-07
and compensation values are for the last fiscal
year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of
options exercised during the fiscal year.
| |
|
11.08% Nasdaq 
Profile
